NEW YORK, March 28 (GenomeWeb News) - PerkinElmer and George Mason University will begin a five-year research collaboration to develop proteomic technologies and cancer biomarkers, the partners said today.
As first reported last week in ProteoMonitor, a GenomeWeb News publication, scientists from both organizations will work together to design new proteomic platforms for biomarker discovery.
The new technologies will operate on a "new concept ... that requires both the precise mass and the amino acid sequence of the candidate biomarker," said Emanuel Petricoin of George Mason.
The researchers will use PerkinElmer's Bioxpression platform for biomarker candidates and will be validated in clinical trials.
Financial details were not provided.
The research will focus on stage one lung, ovarian, and breast cancer.